Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Brian Slomovitz MD
Closed to Accrual
Patient must have squamous cell carcinoma with a depth invasion > 1mm.Patients must have T1 or T2 tumors (FIGO staging) < 4cm, not encroaching in urethra, vagina or anus with clinically negative inguinofemoral lymph nodes.Localization and size of the tumor are such that peri-lesional injection of the tracers at three or four sites is possible.Preoperative imaging does not show enlarged (< 1.5 cm) suspicious nodes.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.